Collects samples from people with myeloma and related plasma cell conditions
Collects and stores biological samples from adults with myeloma or related conditions.
Plain-language title generated from the registry record
Registry title: European Myeloma Network (EMN) Sample Project
Key facts
- Where
- Coimbra, Lisbon, and Porto, PortugalSee the 4 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Which of these best describes your myeloma treatment so far?
Source: NCT06237803, who can take part
Where in Portugal
- CHUCCoimbra, PortugalTaking people
- Fundacao ChampalimaudLisbon, PortugalTaking people
- Chsj - Hosp. Sao JoaoPorto, PortugalTaking people
- IPOP PortoPorto, PortugalTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- European Myeloma Network B.V.
- Trial code
- NCT06237803
- Record updated
- 3 December 2025
- Original description
This is an observational, non-interventional, multicenter study for the prospective collection, storage and analysis of patients' biological samples.Read full original descriptionShow less
EMN Prospective Sample Collection Project
This is an observational, non-interventional, multicenter study for the prospective collection, storage and analysis of patients' biological samples.
This study establishes a common international infrastructure useful to collect standard clinical variables at baseline and during treatment and to uniformly collect and store biological samples
Inclusion: Subjects with MGUS, smouldering Multiple Myeloma (SMM) , MM (Multiple Myeloma) (+/- EMD), plasma cell leukemia (PCL) (+/- EMD); Subjects are ≥ 18 years old; Subjects have provided written informed consent in accordance with federal, local, and institutional guidelines prior to initiation of any project-specific activities or procedures; Subjects do not have kind of condition that, in the opinion of the Investigators, may compromise the ability of the subjects to give written informed consent and; subjects are, in the investigator's opinion, willing and able to comply with the protocol requirements.
Exclusion: Previous treatment with anti-myeloma therapy (excluding one course of therapy in patients in which urgent therapy is deemed necessary according to physician's discretion, e.g. myeloma-related complications resistant to supportive care); Subjects have had prior unforeseen (serious) adverse reactions to blood donation including, but not limited to fainting, angina, severe bruising, allergic reactions, or any other adverse events; Any psychological, familial, sociological and geographical condition potentially hampering compliance with the protocol and follow-up schedule.